Open Access
Issue
Med Buccale Chir Buccale
Volume 20, Number 3, juillet 2014
Page(s) 177 - 183
Section Cas clinique et revue de littérature / Up-to date Review and Case Report
DOI https://doi.org/10.1051/mbcb/2014015
Published online 19 September 2014
  1. International osteoporosis foundation. Facts and statistics. http://www.iofbonehealth.org/facts-statistics (consulté le 12/03/2014). [Google Scholar]
  2. Dutheil N, Scheidegger S. Les pathologies des personnes âgées vivant en établissement. DREES, Études et résultats 2006; 494:5-7. [Google Scholar]
  3. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376. [Google Scholar]
  4. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491. [CrossRef] [PubMed] [Google Scholar]
  5. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-253. [CrossRef] [PubMed] [Google Scholar]
  6. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587. [CrossRef] [PubMed] [Google Scholar]
  7. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-971. [PubMed] [Google Scholar]
  8. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-623. [CrossRef] [PubMed] [Google Scholar]
  9. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-836. [CrossRef] [PubMed] [Google Scholar]
  10. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009; 122:33-45. [CrossRef] [Google Scholar]
  11. Fleisch H. Bisphosphonates-preclinical. In: Fleich H, ed. Bisphosphonates in bone disease: From the Laboratory to the Patient. 4th ed. Academic Press, San Diego, 2000, pp. 27-66. [Google Scholar]
  12. Abi Najm S, Lesclous Ph, Lombardi T, Bouzouita I, Carrel JP, Samson J. Ostéonécrose des maxillaires due aux bisphosphonates : mise au point. Med Buccale Chir Buccale 2008;14:5-18. [CrossRef] [EDP Sciences] [Google Scholar]
  13. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117. [CrossRef] [PubMed] [Google Scholar]
  14. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-1575. [CrossRef] [PubMed] [Google Scholar]
  15. Ruggiero SL, Mehrotra B, Rosenberg TF, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534. [CrossRef] [PubMed] [Google Scholar]
  16. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761. [CrossRef] [PubMed] [Google Scholar]
  17. Gander T, Obwegeser JA, Zemann W, Grätz KW, Jacobsen C. Malignancy mimicking bisphosphonate-associated osteonecrosis of the jaw: a case series and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:32-36. [CrossRef] [PubMed] [Google Scholar]
  18. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl): 2-12. [CrossRef] [Google Scholar]
  19. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent 2014; doi: 10.1155/2014/107690. Epub 2014 Feb 6. [Google Scholar]
  20. Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP, et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis 2012;18:625-632. [CrossRef] [PubMed] [Google Scholar]
  21. Lesclous P, Grabar S, Abi Najm S, Carrel JP, Lombardi T, Saffar JL, Samson J. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Investig 2014;18:391-399. [CrossRef] [Google Scholar]
  22. Urade M, Tanaka M, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 2011;69:e364-371. [CrossRef] [PubMed] [Google Scholar]
  23. Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Maxillofac Surg 2012; 70:1573-1583. [CrossRef] [Google Scholar]
  24. Angiero F, Sannino C, Borloni R, Crippa R, Benedicenti S, Romanos GE. Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er: YAG laser. Lasers Med Sci 2009;24:849-856. [CrossRef] [PubMed] [Google Scholar]
  25. Vescovi B, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd: YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007;45:628-632. [CrossRef] [PubMed] [Google Scholar]
  26. Ordre national des chirurgiens-dentistes. Les principaux réseaux de soins. http://www.ordre-chirurgiens-dentistes.fr/grand-public/reseaux-de-soins/les-principaux-reseaux-de-soins.html (consulté le 12 mars 2014). [Google Scholar]
  27. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.